secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0000950170-25-016708
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular reports positive 52-week Phase 2b data for wet AMD therapy 4D-150
------------------------------------------------------------------------------

- Phase 2b (n=30): 83% reduction in supplemental aflibercept injections (0.97 mean vs 6.0 on-label); 57% injection-free over 52 weeks.
- Recently diagnosed subgroup (n=15): 94% reduction (0.33 mean injections); 80% injection-free.
- Safety: well tolerated up to 3 years; 2.8% (2/71) 4D-150-related 1+ IOI; no hypotony, endophthalmitis, or vasculitis.
- Durable aflibercept expression up to 2 years; aqueous humor levels consistently within projected therapeutic range.
- Phase 3 trials 4FRONT-1 (Q1 2025) and 4FRONT-2 (Q3 2025) to initiate; topline 52-week data expected H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025016708/0000950170-25-016708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025016708/fdmt-20250208.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-016708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer